<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30146351</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>29</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1938-0666</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>18</Volume>                    <Issue>5</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Clinical breast cancer</Title>                <ISOAbbreviation>Clin. Breast Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Genetic Markers in Triple-Negative Breast Cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>e841-e850</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S1526-8209(18)30093-4</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clbc.2018.07.023</ELocationID>            <Abstract>                <AbstractText>Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancer cases and is characterized by the absence of estrogen, progesterone, and human epidermal growth factor 2 receptors. Though TNBC is a highly heterogenic and aggressive disease, TNBC patients have better response to neoadjuvant therapy compared to other breast cancer subtypes. Nevertheless, patients with residual disease have a very poor prognosis, with higher probability of relapse and lower overall survival in the first years after diagnosis. TNBC has 6 subtypes with distinct molecular signatures with different prognoses and probably different responses to therapy. The precise stratification of TNBC is therefore crucial for the development of potent standardized and targeted therapies. In spite of intensive research into finding new molecular biomarkers and designing personalized therapeutic approaches, BRCA mutational status is the only clinically validated biomarker for personalized therapy in TNBC. Recent studies have reported several promising biomarkers that are currently being validated through clinical trials. The objective of this review was to summarize the clinically relevant genetic markers for TNBC that could serve as diagnostic, prognostic, or predictive or could improve personalized therapeutic strategies.</AbstractText>                <CopyrightInformation>Copyright Â© 2018 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Sporikova</LastName>                    <ForeName>Zuzana</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Olomouc, Czech Republic.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Koudelakova</LastName>                    <ForeName>Vladimira</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Olomouc, Czech Republic. Electronic address: vladimira.koudelakova@upol.cz.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Trojanec</LastName>                    <ForeName>Radek</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Olomouc, Czech Republic.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hajduch</LastName>                    <ForeName>Marian</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Olomouc, Czech Republic.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>04</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Clin Breast Cancer</MedlineTA>            <NlmUniqueID>100898731</NlmUniqueID>            <ISSNLinking>1526-8209</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">BRCA</Keyword>            <Keyword MajorTopicYN="N">Predictor</Keyword>            <Keyword MajorTopicYN="N">Prognosis</Keyword>            <Keyword MajorTopicYN="N">Targeted therapy</Keyword>            <Keyword MajorTopicYN="N">p53</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>16</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>06</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30146351</ArticleId>            <ArticleId IdType="pii">S1526-8209(18)30093-4</ArticleId>            <ArticleId IdType="doi">10.1016/j.clbc.2018.07.023</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>